Report cover image

Cancer Microbiome Sequencing Market by Product (Kits & Assays, Service, Software), Technology (Next-Generation Sequencing, Polymerase Chain Reaction), Application, End User - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 182 Pages
SKU # IRE18436666

Description

Cancer Microbiome Sequencing Market by Product (Kits & Assays, Service, Software), Technology (Next-Generation Sequencing, Polymerase Chain Reaction), Application, End User - Global Forecast 2024-2030


The Cancer Microbiome Sequencing Market size was estimated at USD 1.74 billion in 2023 and expected to reach USD 1.84 billion in 2024, at a CAGR 5.79% to reach USD 2.59 billion by 2030.

Global Cancer Microbiome Sequencing Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Microbiome Sequencing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Microbiome Sequencing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Microbiome Sequencing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., AstraZeneca PLC, Athos Therapeutics Inc., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb, CosmosID, Creative Biolabs, Evelo Biosciences, EzBiome, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals, Illumina, Inc., LC Sciences, Merck KGaA, Metagen Therapeutics, MV BioTherapeutics SA, Norgen Biotek Corp., Novogene Co, Ltd., Qiagen NV, Thermo Fisher Scientific Inc., Vedanta Biosciences., and Viome Life Sciences, Inc..

Market Segmentation & Coverage



This research report categorizes the Cancer Microbiome Sequencing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Kits & Assays
Service
Software
Technology
Next-Generation Sequencing
Polymerase Chain Reaction
Application
Diagnostics
Translational Research
End User
Academic & Research Institutes
Hospitals & Diagnostic Laboratories
Pharmaceutical & Biotechnology Companies
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cancer Microbiome Sequencing Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Microbiome Sequencing Market?
3. What are the technology trends and regulatory frameworks in the Cancer Microbiome Sequencing Market?
4. What is the market share of the leading vendors in the Cancer Microbiome Sequencing Market?
5. Which modes and strategic moves are suitable for entering the Cancer Microbiome Sequencing Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

182 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cancer Microbiome Sequencing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising number of cancer cases across the world
5.1.1.2. Government initiatives to promote cancer prevention, diagnosis, and care
5.1.1.3. Growing number of research activities and increasing awareness about the significance of gut microbiome
5.1.2. Restraints
5.1.2.1. High cost of availing sequencing services and lack of skilled personnel
5.1.3. Opportunities
5.1.3.1. Advancements in next-generation sequencing
5.1.3.2. Utilization of AI, ML, and bioinformatics to enable cancer detection
5.1.4. Challenges
5.1.4.1. Technical limitations and difficulties associated with data analysis
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cancer Microbiome Sequencing Market, by Product
6.1. Introduction
6.2. Kits & Assays
6.3. Service
6.4. Software
7. Cancer Microbiome Sequencing Market, by Technology
7.1. Introduction
7.2. Next-Generation Sequencing
7.3. Polymerase Chain Reaction
8. Cancer Microbiome Sequencing Market, by Application
8.1. Introduction
8.2. Diagnostics
8.3. Translational Research
9. Cancer Microbiome Sequencing Market, by End User
9.1. Introduction
9.2. Academic & Research Institutes
9.3. Hospitals & Diagnostic Laboratories
9.4. Pharmaceutical & Biotechnology Companies
10. Americas Cancer Microbiome Sequencing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cancer Microbiome Sequencing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cancer Microbiome Sequencing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Agilent Technologies, Inc.
14.1.3. AstraZeneca PLC
14.1.4. Athos Therapeutics Inc.
14.1.5. Bio-Rad Laboratories, Inc.
14.1.6. Bristol-Myers Squibb
14.1.7. CosmosID
14.1.8. Creative Biolabs
14.1.9. Evelo Biosciences
14.1.10. EzBiome
14.1.11. F. Hoffmann-La Roche AG
14.1.12. Ferring Pharmaceuticals
14.1.13. Illumina, Inc.
14.1.14. LC Sciences
14.1.15. Merck KGaA
14.1.16. Metagen Therapeutics
14.1.17. MV BioTherapeutics SA
14.1.18. Norgen Biotek Corp.
14.1.19. Novogene Co, Ltd.
14.1.20. Qiagen NV
14.1.21. Thermo Fisher Scientific Inc.
14.1.22. Vedanta Biosciences.
14.1.23. Viome Life Sciences, Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. CANCER MICROBIOME SEQUENCING MARKET RESEARCH PROCESS
FIGURE 2. CANCER MICROBIOME SEQUENCING MARKET SIZE, 2023 VS 2030
FIGURE 3. CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CANCER MICROBIOME SEQUENCING MARKET DYNAMICS
FIGURE 7. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 10. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 12. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 14. CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. CANCER MICROBIOME SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. CANCER MICROBIOME SEQUENCING MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us